Novo Nordisk(US:NVO) 智通财经网·2025-09-18 14:00Core Viewpoint - Novo Nordisk's stock rose by 5% to $61.13 following a Medicare data study indicating that patients using its diabetes drug Ozempic have a 23% lower risk of heart attack, stroke, or death compared to those using Eli Lilly's Trulicity [1] Group 1: Company Performance - Novo Nordisk's stock price increased significantly, reflecting positive market sentiment driven by new research findings [1] - The study involved nearly 60,000 patients with diabetes and heart disease, highlighting the effectiveness of Ozempic [1] Group 2: Competitive Landscape - The results of the study provide strong support for Novo Nordisk in the competitive landscape against Eli Lilly, particularly in the weight loss drug market [1] - Eli Lilly is gaining market share with its newer drugs Mounjaro and Zepbound, creating significant pressure on Novo Nordisk [1]